Clinical relevance of patient-reported outcomes: new threshold proves to be practical


18 February 2021 - Current examples show that the 15% threshold newly set by IQWiG for the recognition of responder analyses in the early benefit assessment of drugs works.

In order to show the clinical relevance of a difference between two treatment alternatives, the submitted manufacturer dossiers have been increasingly containing responder analyses for patient-relevant outcomes as part of the early benefit assessment of new drugs.

Read IQWiG press release

Michael Wonder

Posted by:

Michael Wonder